

ESPI Current Report

Number: 25/2024
 Date of preparation: September 27, 2024
 Company: Genomtec SA based in Wrocław

Title	Information about recognition by NCBR of the grant received by the Company as implemented
-------	--

Legal basis: Article 17 section 1 of MAR - confidential information

Report Content: The Management Board of Genomtec S.A. with its registered office in Wrocław ("Issuer", "Company") hereby announces that on September 27, 2024, the Company received information from the National Centre for Research and Development (NCBR) about the NCBR recognizing the project implemented by the Company under the name: "Development of mobile diagnostic equipment based on the lab-on-chip solution for detecting COVID-19 disease (SARS-CoV-2 virus)" (Project) as completed in terms of content and finances.

The project was co-financed by NCBR, and in accordance with the co-financing agreement with NCBR, the Company is obliged to ensure the durability of the Project for a period of 3 years.

The total cost of the Project amounted to approximately PLN 10.3 million, the funding granted by NCBR amounted to approximately PLN 6.7 million.

As part of the Project, the Company has developed and tested a multiplex kit for the genetic identification of the SARS-CoV-2 virus using the RT-LAMP technique for use in diagnostic laboratories and a POCT diagnostic system based on the lab-on-chip solution and the RT-LAMP technique for detecting the SARS-CoV-2 virus in distributed diagnostics.

Signatures of persons representing the Company:
 Michał Wachowski - Member of the Management Board